相似文献
1
Dimerization of soluble major histocompatibility complex-peptide complexes is sufficient for activation of T cell hybridoma and induction of unresponsiveness.
J Exp Med. 1995 Aug 1;182(2):439-47. doi: 10.1084/jem.182.2.439.
2
CD8 T cells, like CD4 T cells, are triggered by multivalent engagement of TCRs by MHC-peptide ligands but not by monovalent engagement.
J Immunol. 2006 Feb 1;176(3):1498-505. doi: 10.4049/jimmunol.176.3.1498.
3
Inhibition of an allospecific T cell hybridoma by soluble class I proteins and peptides: estimation of the affinity of a T cell receptor for MHC.
Cell. 1989 Jan 13;56(1):47-55. doi: 10.1016/0092-8674(89)90982-3.
4
Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.
Eur J Immunol. 1991 Dec;21(12):2963-70. doi: 10.1002/eji.1830211210.
5
Analysis of peptide binding patterns in different major histocompatibility complex/T cell receptor complexes using pigeon cytochrome c-specific T cell hybridomas. Evidence that a single peptide binds major histocompatibility complex in different conformations.
J Exp Med. 1989 Nov 1;170(5):1609-25. doi: 10.1084/jem.170.5.1609.
6
Primary cytotoxic T lymphocyte induction using peptide-stripped autologous cells.
Int Immunol. 1994 Nov;6(11):1759-66. doi: 10.1093/intimm/6.11.1759.
7
Presentation of a self-peptide for in vivo tolerance induction of CD4+ T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus.
J Exp Med. 1995 Nov 1;182(5):1481-91. doi: 10.1084/jem.182.5.1481.
8
Glu227-->Lys substitution in the acidic loop of major histocompatibility complex class I alpha 3 domain distinguishes low avidity CD8 coreceptor and avidity-enhanced CD8 accessory functions.
J Exp Med. 1996 Nov 1;184(5):1671-83. doi: 10.1084/jem.184.5.1671.
9
CD4 and CD8 accessory molecules function through interactions with major histocompatibility complex molecules which are not directly associated with the T cell receptor-antigen complex.
Eur J Immunol. 1991 Oct;21(10):2507-15. doi: 10.1002/eji.1830211030.
引用本文的文献
1
SCHOOL of nature: ligand-independent immunomodulatory peptides.
Drug Discov Today. 2020 Aug;25(8):1298-1306. doi: 10.1016/j.drudis.2020.05.005. Epub 2020 May 12.
2
A window of opportunity for cooperativity in the T Cell Receptor.
Nat Commun. 2018 Jul 5;9(1):2618. doi: 10.1038/s41467-018-05050-6.
3
Linking form to function: Biophysical aspects of artificial antigen presenting cell design.
Biochim Biophys Acta. 2015 Apr;1853(4):781-90. doi: 10.1016/j.bbamcr.2014.09.001. Epub 2014 Sep 6.
4
Receptor Pre-Clustering and T cell Responses: Insights into Molecular Mechanisms.
Front Immunol. 2014 Apr 30;5:132. doi: 10.3389/fimmu.2014.00132. eCollection 2014.
5
Soluble MOG35-55/I-A(b) dimers ameliorate experimental autoimmune encephalomyelitis by reducing encephalitogenic T cells.
PLoS One. 2012;7(10):e47435. doi: 10.1371/journal.pone.0047435. Epub 2012 Oct 15.
6
Antigen-specific therapeutic approaches in Type 1 diabetes.
Cold Spring Harb Perspect Med. 2012 Feb;2(2):a007773. doi: 10.1101/cshperspect.a007773.
7
In vivo priming of IL-17(+) uveitogenic T cells is enhanced by Toll ligand receptor (TLR)2 and TLR4 agonists via γδ T cell activation.
Mol Immunol. 2012 Mar;50(3):125-33. doi: 10.1016/j.molimm.2011.12.013. Epub 2012 Feb 1.
8
MHC class I dimer formation by alteration of the cellular redox environment and induction of apoptosis.
Immunology. 2012 Feb;135(2):133-9. doi: 10.1111/j.1365-2567.2011.03518.x.
9
The SCHOOL of nature: I. Transmembrane signaling.
Self Nonself. 2010 Jan;1(1):4-39. doi: 10.4161/self.1.1.10832.
10
Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach?
J Mol Med (Berl). 2011 Aug;89(8):733-42. doi: 10.1007/s00109-011-0757-z. Epub 2011 Apr 16.
本文引用的文献
1
Real-time measurement of antigenic peptide binding to empty and preloaded single-chain major histocompatibility complex class I molecules.
Eur J Immunol. 1993 May;23(5):1118-24. doi: 10.1002/eji.1830230521.
2
Tetramer data reinterpreted.
Nature. 1993 Mar 4;362(6415):23-4. doi: 10.1038/362023b0.
3
Interaction of papain-digested HLA class I molecules with human alloreactive cytotoxic T lymphocytes (CTL).
Clin Exp Immunol. 1993 Jan;91(1):183-8. doi: 10.1111/j.1365-2249.1993.tb03376.x.
4
A soluble, single-chain Kd molecule produced by yeast selects a peptide repertoire indistinguishable from that of cell-surface-associated Kd.
Eur J Immunol. 1993 Aug;23(8):1776-83. doi: 10.1002/eji.1830230807.
5
T cell activation by clustered tyrosine kinases.
Cell. 1993 Jul 16;74(1):171-83. doi: 10.1016/0092-8674(93)90304-9.
6
Signal transduction by lymphocyte antigen receptors.
Cell. 1994 Jan 28;76(2):263-74. doi: 10.1016/0092-8674(94)90334-4.
7
Positive selection of lymphocytes.
Cell. 1994 Jan 28;76(2):219-28. doi: 10.1016/0092-8674(94)90330-1.
8
Immobilized anti-TCR mAb induces split functions in a CD8+ CTL clone.
Cell Immunol. 1994 Jan;153(1):105-16. doi: 10.1006/cimm.1994.1009.
9
High sensitivity, low affinity--paradox of T-cell receptor recognition.
Curr Opin Immunol. 1994 Feb;6(1):9-12. doi: 10.1016/0952-7915(94)90027-2.
10
The V beta complementarity determining region 1 of a major histocompatibility complex (MHC) class I-restricted T cell receptor is involved in the recognition of peptide/MHC I and superantigen/MHC II complex.
J Exp Med. 1994 Apr 1;179(4):1087-97. doi: 10.1084/jem.179.4.1087.
Zotero 插件